|
|
|
|
Advances in managing epilepsy
Even with newer medications and surgical options, the goal of optimal patient management remains the same: seizure free without side effects.
|
| |
More>>
|
|
|
|
|
|
Natalizumab: FDA is concerned-should managed care be, too?
FDA officials said the agency "remains very concerned" that
patients who take natalizumab may
develop a rare, potentially fatal brain infection called
progressive multifocal leukoencephalopathy (PML). So starts a
report from Reuters published on February 15, 2006. Should managed
care also be concerned?
|
| |
More>>
|
|
|
|
|
|
The 15-minute Visit:
Restless legs syndrome
A 42-year-old woman presents to the clinic complaining of fatigue for the past month. She denies heart palpitations, shortness of breath, pain, or changes in appetite or weight. Further questioning reveals that she has trouble sleeping; she often tosses and turns in bed. She also describes a crawling sensation in both legs, which only occurs in the evenings and improves with activity. The patient is happily married and works as a librarian. She has been smoking 1 pack of cigarettes per day for the past 20 years. She denies alcohol or drug use and does not take any medications.
|
| |
More>>
|
|
|
|
|
|
Researchers improve epilepsy treatment
This year's American Academy of Neurology (AAN) meeting featured key drug trials for diseases ranging from epilepsy to Alzheimer's disease (AD) to multiple sclerosis (MS). About 1% of all children up to the age of 16 are affected by epilepsy. Despite broadened and improved pharmacologic options, about 25% of these are refractory to standard therapy.
|
| |
More>>
|
|
|